Daewoong Pharmaceutical’s SGLT-2 inhibitor, ‘Envlo’ can be prescribed at general hospitals in Korea.

According to industry sources, the diabetes treatment Envlo (Enavogliflozin) that was released with reimbursement in May passed the drug committees (DCs) of various medical institutions in Korea including the Samsung Medical Center and Korea University Anam Hospital.

Envlo, which was approved as the 36th new homegrown drug, is the first SGLT-2 inhibitor class diabetes drug that a Korean pharmaceutical company succeeded development and localization of.

Priced at KRW 611, Envlo may be used as ▲monotherapy, ▲metformin combination therapy, and metformin and gemigliptin c